Navigation Links
Digirad Signs Exclusive International Distribution Agreement with Dilon Diagnostics
Date:8/22/2013

SUWANEE, Ga. and NEWPORT NEWS, Va., Aug. 22, 2013 /PRNewswire/ -- Digirad Corporation (NASDAQ: DRAD),  the leader in solid-state diagnostic imaging technology and services, and Dilon Diagnostics, the world leader in molecular breast imaging, today announced that they have signed an exclusive international distribution agreement for Dilon to distribute Digirad's lines of nuclear imaging cameras including the ergo™, a large field-of-view general purpose imaging system, the Cardius® x.act, a triple-head cardiac dedicated SPECT imaging system with VCT Attenuation Correction, and the Cardius® XPO dedicated cardiac SPECT imaging systems line.  The agreement covers distribution of Digirad products to most countries outside the United States.  The signing of this agreement furthers the relationship that Digirad and Dilon have been building since the two companies signed a technology development agreement in mid-2010.

(Logo:  http://photos.prnewswire.com/prnh/20130501/PH05456LOGO )

Digirad President and CEO Matthew G. Molchan said, "We are very pleased with this enhanced relationship with Dilon and the opportunity to further expand our product reach beyond the United States.  We continue to believe that our nuclear imaging cameras, with their solid-state design and technology, are well suited to meet the needs of the international market and we are very excited to partner with Dilon to distribute our cameras around the world.  We believe our products will be an excellent complement to the already extensive Dilon product line up."   

Dilon Diagnostics Chairman and CEO Robert G. Moussa said, "We are extremely pleased to expand our already successful partnership with Digirad and are excited to broaden our offering of nuclear imaging products in the international marketplace.  With the addition of the Digirad cameras to the existing Dilon product portfolio, we now have the ability to offer a full spectrum of diagnostic imaging solutions to our international customers and to afford the excellent range of Digirad's nuclear imaging products access to our broad international network of customers."

About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies, Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/BSGI. MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon's GammaLoc® System is the only localization device on the market to enable molecular-guided breast biopsy. Many leading medical centers around the country are now offering MBI to their patients, including: Beth Israel and Cornell University Medical Centers in New York; Kaiser Permanente of Sacramento, CA and The George Washington University, Washington D.C. For more information on Dilon Diagnostics please visit www.dilon.com.

About Digirad Corporation
Digirad is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.

Media Contact: Pjerin Luli
Dilon Technologies, Inc.
757-269-4910 x 321
pluli@dilon.com


'/>"/>
SOURCE Dilon Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
2. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
3. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
4. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
5. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
6. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
7. Bacterin International Signs Its Third National GPO Contract with Novation
8. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
9. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
10. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
11. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
(Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):